Constipation diagnostic study of choice

Jump to: navigation, search

Constipation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Constipation from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Abdominal X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Constipation On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Constipation

All Images
X-rays
Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Constipation

CDC on Constipation

Constipation in the news

Blogs on Constipation

Directions to Hospitals Treating Constipation

Risk calculators and risk factors for Constipation

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

Diagnostic study of choice for constipation is ROME III criteria. Rome III criteria includes symptom onset for more than 6 months and two or more number of specific symptoms. Specific symptoms of constipation include straining, hard stool, sensation of incomplete evacuation, sensation of obstruction, necessity of manual maneuvers, less than 3 bowel movements per week, lack of loose stool, and lack of irritable bowel syndrome (IBS).

Diagnostic Study of Choice

The diagnostic criteria based on the American Gastroenterological Association (AGA), Rome III criteria, and pharmacologic studies based criteria are as follows:[1][2][3]

Rome III criteria[1][2] Pharmacologic studies based criteria[1][3]
Symptom onset for ≥ 6 months and ≥ 2 of the following for the past 3 months: Spontaneous bowel movements < 3 per week and ≥ 1 of the following for at least 12 weeks during the past 12 months:

References

  1. 1.0 1.1 1.2 Bharucha AE, Pemberton JH, Locke GR (2013). "American Gastroenterological Association technical review on constipation.". Gastroenterology. 144 (1): 218–38. PMC 3531555Freely accessible. PMID 23261065. doi:10.1053/j.gastro.2012.10.028. 
  2. 2.0 2.1 Longstreth, GF.; Thompson, WG.; Chey, WD.; Houghton, LA.; Mearin, F.; Spiller, RC. (2006). "Functional bowel disorders.". Gastroenterology. 130 (5): 1480–91. PMID 16678561. doi:10.1053/j.gastro.2005.11.061. 
  3. 3.0 3.1 Lembo, AJ.; Kurtz, CB.; Macdougall, JE.; Lavins, BJ.; Currie, MG.; Fitch, DA.; Jeglinski, BI.; Johnston, JM. (2010). "Efficacy of linaclotide for patients with chronic constipation.". Gastroenterology. 138 (3): 886–95.e1. PMID 20045700. doi:10.1053/j.gastro.2009.12.050. 



Linked-in.jpg